# NCT03914612 (NCT03914612)

> Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03914612
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: National Cancer Institute (NCI)
- Conditions: Endometrial Clear Cell Adenocarcinoma; Endometrial Dedifferentiated Carcinoma; Endometrial Endometrioid Adenocarcinoma; Endometrial Mixed Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Endometrial Adenocarcinoma; Recurrent Endometrial Carcinoma; Recurrent Endometrial Clear Cell Adenocarcinoma; Recurrent Endometrial Dedifferentiated Carcinoma; Recurrent Endometrial Endometrioid Adenocarcinoma; Recurrent Endometrial Mixed Cell Adenocarcinoma; Recurrent Endometrial Serous Adenocarcinoma; Recurrent Endometrial Undifferentiated Carcinoma; Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8; Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
- Interventions: Carboplatin; Computed Tomography; Paclitaxel; Pembrolizumab; Placebo Administration; Quality-of-Life Assessment; Questionnaire Administration
- Enrollment: 813
- Primary outcome: Progression-free Survival (PFS)

## Commentary we found

- YouTube: 31
- Podcasts: 23
- X threads: 10

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct03914612

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03914612", "email": "<work email>"}; the inbox owner confirms by the emailed link.